search panel

Current News

  • Geoffrey Ogram Memorial Research Fund

    Geoffrey Ogram Memorial Research Fund

    The Geoffrey Ogram Memorial Research Fund has been established to foster innovative research in lung cancer.

    Being a never-smoker, Geoffrey Ogram was shocked to receive a diagnosis of lung cancer in 2010. Despite two years of non-progression, successful surgery and targeted therapy, Geoffrey passed away on Friday April 15th, 2016. Geoffrey was a tireless activist for lung cancer awareness and research.

    Read More

  • LCC Summer Studentship Grant Program

    LCC Summer Studentship Grant Program

    The Lung Cancer Canada Summer Studentship Grant Program provides support for highly qualified applicants in all areas of lung cancer health research at all post-secondary stages to add to their experience by engaging in health research in Canada.  A number of $5,000 (CDN) grants are available as a one-time funding opportunity.

    Read More

  • pCODR invites stakeholders’ input on Pembrolizumab (Keytruda) for NSCLC

    pCODR invites stakeholders’ input on Pembrolizumab (Keytruda) for NSCLC

    Please contact Lung Cancer Canada (info@lungcancercanada.ca) if you are a patient or caregiver of a patient on Keytruda.  Your experience with this treatment is a crucial part of the decision process!

    Read More

  • Renowned Public Health Physician's Battle Against Disease Was Personal

    Renowned Public Health Physician's Battle Against Disease Was Personal

    Tenacious Dr. Terry-Nan Tannenbaum, renowned public health physician, fought super-bugs, SARS, tuberculosis and HIV in others for decades until her fight became personal when she was diagnosed with terminal lung cancer.

    Read More

  • Dr. Juergens' Interview with CTV News

    Dr. Juergens' Interview with CTV News

    Dr. Rosalyn Juergens' interview with Pauline Chan at CTV News on the promising results from the drug Opdivo (Nivolomab).

    Read More

  • pCODR Releases Initial Recommendation of Opdivo

    pCODR Releases Initial Recommendation of Opdivo

    pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.  

    This is a great news for NSCLC patients!  We hope to see more like this for other types of lung cancer.

    Read More

Latest Tweets